BTAI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BioXcel Therapeutics Inc (BTAI) is not a good buy for a beginner investor with a long-term strategy at this time. The stock exhibits bearish technical indicators, weak financial performance, and lacks strong positive catalysts. Additionally, there are no significant trading signals or recent news to support a bullish case.
The technical indicators are bearish. The MACD is negatively expanding, RSI is neutral but leaning towards oversold territory, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 1.388, with no clear signs of reversal.
Rodman & Renshaw initiated coverage with a Buy rating and a $17 price target, citing the company's differentiated at-home agitation franchise and potential in neuropsychiatry.
H.C. Wainwright lowered the price target from $10 to $6 due to anticipated equity dilution. Financials show a significant YoY revenue drop (-54.21%) and worsening EPS (-57.67%). Gross margin has also declined drastically (-119.87%). No recent news or significant trading trends from insiders or hedge funds.
In Q3 2025, revenue dropped by -54.21% YoY to $98,000. Net income improved but remains negative at -$30.91M. EPS dropped to -2.18 (-57.67% YoY), and gross margin fell to 88.78 (-119.87% YoY). Overall, the financial performance is weak.
Analysts are mixed. Rodman & Renshaw has a Buy rating with a $17 price target, while H.C. Wainwright lowered its price target from $10 to $6 citing equity dilution concerns.
